Asian Penny Stocks With Market Caps Under US$2B To Consider
Amidst the backdrop of geopolitical tensions and fluctuating energy prices, Asian markets are navigating a complex landscape that has investors on edge. While large-cap stocks often dominate headlines, penny stocks—despite their old-fashioned name—remain an intriguing option for those seeking to explore smaller or newer companies with potential upside. By focusing on firms with strong financials and growth prospects, investors can uncover hidden value in these lesser-known equities.
Name
Share Price
Market Cap
Financial Health Rating
Guoquan Food (Shanghai) (SEHK:2517)
HK$4.15
HK$10.91B
★★★★★★
Activation Group Holdings (SEHK:9919)
HK$0.96
HK$714.95M
★★★★★★
North East Rubber (SET:NER)
THB4.88
THB9.02B
★★★★☆☆
Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)
We’ll examine a selection from our screener results.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Jinhai Medical Technology Limited is an investment holding company offering minimally invasive surgery solutions, medical products, and related services in China and Singapore, with a market cap of HK$11.85 billion.
Operations: Revenue segments for the company have not been reported.
Market Cap: HK$11.85B
Jinhai Medical Technology Limited, with a market cap of HK$11.85 billion, is currently unprofitable but has demonstrated some financial stability by maintaining more cash than its total debt and covering both short and long-term liabilities with its short-term assets. Despite a decline in revenue from SGD 50.24 million to SGD 46.28 million for the year ended December 31, 2025, the company reduced its net loss slightly to SGD 17.08 million. Its board and management team are experienced, with recent leadership changes including the appointment of Mr. Li Bin as co-chairman to potentially bolster strategic direction.
SEHK:2225 Financial Position Analysis as at Mar 2026
Simply Wall St Financial Health Rating: ★★★★★★
Overview: PAX Global Technology Limited is an investment holding company that develops and sells electronic funds transfer point-of-sale products across Hong Kong, China, the United States, and Italy, with a market cap of HK$4.46 billion.
Operations: The company’s revenue primarily comes from its e-Payment Terminal Solutions Business, generating HK$5.87 billion.
Market Cap: HK$4.46B
PAX Global Technology, with a market cap of HK$4.46 billion, has shown resilience despite challenges in the electronic funds transfer sector. The company reported revenues of HK$5.87 billion for 2025, slightly down from the previous year, but net income increased to HK$753.59 million. It remains debt-free and maintains strong short-term asset coverage over liabilities (HK$8.5 billion vs HK$2 billion). However, its management and board are relatively inexperienced with average tenures under three years. Despite trading significantly below estimated fair value and stable earnings quality, recent dividend cuts may concern income-focused investors.
SEHK:327 Debt to Equity History and Analysis as at Mar 2026
Simply Wall St Financial Health Rating: ★★★★★★
Overview: HARBIN GLORIA PHARMACEUTICALS Co., LTD focuses on the research, development, production, and sale of pharmaceutical products in China with a market cap of CN¥7.51 billion.
Operations: Currently, there are no specific revenue segments reported for this company.
Market Cap: CN¥7.51B
Harbin Gloria Pharmaceuticals, with a market cap of CN¥7.51 billion, has demonstrated significant earnings growth of 265.4% over the past year, surpassing industry averages. Despite a low return on equity at 13.7%, the company has reduced its debt-to-equity ratio from 79% to 3.2% in five years and holds more cash than total debt, indicating financial prudence. Short-term assets exceed both short- and long-term liabilities, ensuring liquidity stability. However, recent financial results were impacted by a large one-off gain of CN¥123.2 million, which may not reflect ongoing operational performance accurately amidst recent board changes and governance updates.
SZSE:002437 Financial Position Analysis as at Mar 2026
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:2225 SEHK:327 and SZSE:002437.
This article was originally published by Simply Wall St.
